- Home
- AAPG vs APLS Comparison
AAPG vs APLS Comparison
Compare AAPG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAPG
- APLS
- Stock Information
- Founded
- AAPG 2009
- APLS 2009
- Country
- AAPG China
- APLS United States
- Employees
- AAPG N/A
- APLS N/A
- Industry
- AAPG Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- AAPG Health Care
- APLS Health Care
- Exchange
- AAPG Nasdaq
- APLS Nasdaq
- Market Cap
- AAPG 2.2B
- APLS 2.2B
- IPO Year
- AAPG 2025
- APLS 2017
- Fundamental
- Price
- AAPG $24.40
- APLS $16.93
- Analyst Decision
- AAPG Buy
- APLS Buy
- Analyst Count
- AAPG 1
- APLS 19
- Target Price
- AAPG N/A
- APLS $37.50
- AVG Volume (30 Days)
- AAPG 14.1K
- APLS 2.9M
- Earning Date
- AAPG 06-10-2025
- APLS 05-07-2025
- Dividend Yield
- AAPG N/A
- APLS N/A
- EPS Growth
- AAPG N/A
- APLS N/A
- EPS
- AAPG N/A
- APLS N/A
- Revenue
- AAPG $134,352,180.00
- APLS $775,839,000.00
- Revenue This Year
- AAPG N/A
- APLS $1.54
- Revenue Next Year
- AAPG $389.09
- APLS $22.80
- P/E Ratio
- AAPG N/A
- APLS N/A
- Revenue Growth
- AAPG 341.77
- APLS 48.04
- 52 Week Low
- AAPG $16.50
- APLS $16.10
- 52 Week High
- AAPG $26.55
- APLS $43.76
- Technical
- Relative Strength Index (RSI)
- AAPG N/A
- APLS 41.44
- Support Level
- AAPG N/A
- APLS $16.61
- Resistance Level
- AAPG N/A
- APLS $17.48
- Average True Range (ATR)
- AAPG 0.00
- APLS 0.86
- MACD
- AAPG 0.00
- APLS 0.09
- Stochastic Oscillator
- AAPG 0.00
- APLS 28.47
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.